In keeping with the new trend for providing "living guidelines," the Global Initiative for Asthma (GINA) Scientific Committee released their latest update a few months ago. The push toward earlier ...

The EMERGENT-3 trial, published in the Journal of the American Medical Association Psychiatry, represents a significant advancement in the treatment of schizophrenia, particularly for individuals ...

The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a key ...

MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M 1 ...

KarXT is an oral therapy that combines xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist. The Food and Drug Administration (FDA) has accepted for review the New Drug ...

Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than ...

Coexpression studies involving mutant m 3 muscarinic receptors or m 3 receptor fragments Based on both theoretical and experimental data, Gouldson et al. (1998) recently proposed a model that suggests ...

(Left) Nicotine withdrawal reduces nicotinic receptor activity, leading to a relative increase in muscarinic receptor activity and disrupting acetylcholine signaling balance. (Right) Suppressing ...